Table 1 Patients’ pre-treatment characteristics
Pre-FCR characteristics | n (%) or median [min-max] |
|---|---|
Gender | |
•Men | 112 (69.1) |
•Women | 50 (30.9) |
Age category | |
•>65 years | 58 (35.8) |
•≤65 years | 104 (64.2) |
Binet stage | |
•Binet A | 34 (21.3) |
•Binet B | 85 (53.1) |
•Binet C | 41 (25.6) |
•Missing | 2 |
Time from diagnosis to FCR (months) | 22.1 [0.03-203.00] |
Lymphocytes (G/L) (n=114) | 90.6 [1.30-888.0] |
β2-microglobulin | |
•≤3.5 mg/L | 15 (21.7) |
•>3.5 mg/L | 54 (78.3) |
•Missing | 93 |
LDH value | |
•LDH≤ULN | 52 (45.6) |
•LDH>ULN | 62 (54.4) |
•Missing | 48 |
IGHV mutation status | |
•IGHV-M | 48 (36.6) |
•IGHV-UM | 83 (63.4) |
•Missing | 31 |
Del13q | |
•Del13q | 49 (37.4) |
•No del13q | 82 (62.6) |
•Missing | 31 |
Trisomy 12 | |
•Trisomy 12 | 32 (24.4) |
•No trisomy 12 | 99 (75.6) |
•Missing | 31 |
Del11q | |
•Del11q | 34 (22.2) |
•No del11q | 119 (77.8) |
•Missing | 9 |
Del6q | |
•Del6q | 14 (12.8) |
•No del6q | 95 (87.2) |
•Missing | 53 |
t(14;18)(q32;q21) | |
•t(14;18)(q32;q21) | 5 (4.6) |
•No t(14;18)(q32;q21) | 104 (95.4) |
•Missing | 53 |
Del17p | |
•Del17p | 6 (3.9) |
•No del17p | 146 (96.1) |
•Missing | 10 |
Complex karyotype | |
•Complex karyotype | 87 (78.4) |
•No complex karyotype | 24 (21.6) |
•Missing | 51 |
TP53 mutation | |
•TP53 mutation | 2 (2.9) |
•No TP53 mutation | 68 (97.1) |
•Missing | 92 |
NOTCH1 mutation | |
•NOTCH1 mutation | 11 (16.2) |
•No NOTCH1 mutation | 57 (83.8) |
•Missing | 94 |
SF3B1 mutation | |
•SF3B1 mutation | 6 (8.8) |
•No SF3B1 mutation | 62 (91.2) |
•Missing | 94 |
MYD88 mutation | |
•MYD88 mutation | 1 (1.5) |
•No MYD88 mutation | 66 (98.5) |
•Missing | 95 |
BRAF mutation | |
•No BRAF mutation | 67 (100) |
•Missing | 85 |